| ||||||||||||||
|
|
|||||||||||||
Department of Anesthesiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala
Address correspondence and reprint requests to S. Manikandan, MD, Assistant Professor, Department of Anesthesiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum-695011, Kerala, India. Address e-mail to kanmanis{at}sctimst.ac.in.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
| Case Report |
|---|
|
|
|---|
The patient was scheduled for endoscopic third ventriculostomy for the relief of obstructive hydrocephalus. Premedication consisted of glycopyrrolate 0.2 mg IM 1 h before surgery. The last dose of baclofen was administered 6 h before surgery. In the operating room, the patient was monitored with electrocardiogram, pulse oximetry (Spo2) and a noninvasive arterial blood pressure device. After securing IV access, anesthesia was induced IV with meperidine 40 mg followed by propofol premixed with lidocaine 1 mg/mL. While administering propofol (approximately 60 mg had been injected), the patient developed sudden onset of severe generalized myoclonic type seizures that resulted in dislodgement of the IV line and monitor attachments. The seizures subsided spontaneously within 3 min and the patient had no apparent injury. At this time the patient was unresponsive; however, he was able to maintain his airway with adequate spontaneous breathing. All the monitoring cables were reattached and the peripheral hemoglobin oxygen saturation was 98%. While we were establishing another IV line, the patient showed signs of awakening and an additional dose of propofol (40 mg) was given. Immediately, severe generalized seizures recurred. There was no dislodgement of IV or monitoring lines or injury to the patient. The seizure lasted for 2 min and subsided before institution of any treatment. Thereafter, vecuronium (8 mg IV) was given and the trachea was intubated. Anesthesia was maintained with oxygen, nitrous oxide, and isoflurane. The remainder of the surgical procedure was uneventful and the trachea was extubated successfully. At 8 h and 24 h after surgery, the patient was questioned regarding recall of the abnormal movements and pain during injection of propofol. He did not have any recall.
| Discussion |
|---|
|
|
|---|
The SLP recurred on repeat propofol administration. The temporal sequence between propofol administration and SLP strongly suggests that propofol was the cause of SLP in our patient. Other causes such as pain on IV line insertion or propofol administration were excluded. Meperidine is known to cause SLP as a result of its metabolite, normeperidine. This is an unlikely cause of the SLP observed in our patient because it occurred within 2 minutes of administration (3).
Various neurological sequelae have been described with propofol use, and the majority have been reported to occur after terminating the propofol infusion (4). These neurologic sequelae are thought to be attributable to the interaction of propofol with inhibitory neurotransmitters in the central nervous system, especially
-amino butyric acid (GABA) (5). Convincing evidence supports an interaction of propofol and the GABAA receptor (6). It has been proposed that propofol in clinical doses causes desensitization block of the chloride channel. This prevents further action of GABA on the chloride channels leading to the loss of inhibition of the thalamocortical excitatory circuits of the brain and causing excitatory effects and seizures (7).
Baclofen, a centrally acting muscle relaxant with a half-life of 46 hours, is widely used in the treatment of spasticity of cerebral and spinal origin. Epileptiform discharges have been reported with its use (8) and with its acute withdrawal (9). Although baclofen was not administered in our patient immediately before surgery, baclofen withdrawal syndrome is an unlikely cause of SLP in our patient because therapeutic concentration of the drug in cerebrospinal fluid (CSF) lasts 916 hours (10) and reports indicate the syndrome usually manifests 13 days after sudden stopping of the drug (11).
Baclofen acts by stimulating the GABAB receptor (12). The influence of the GABAB receptor on GABAA-mediated epileptic discharges has been recognized only recently (13). The reduced presynaptic GABAB receptor function in focal cortical dysplastic tissues from patients with refractory epilepsy is thought to facilitate GABAA receptor-mediated epileptiform synchronization as a result of loss of control of GABA release from interneurons (13). Also, it was found that smaller concentrations of baclofen failed to block interictal discharges that were blocked by larger concentration (13). Moreover, baclofen causes acute desensitization of the GABAB receptor that persists up to 4 hours even after washout of the drug, producing persistent epileptiform discharges (14).
The interactions of propofol and baclofen in mediating SLP have not been described. We speculate a similar mechanism could be involved in the occurrence of SLP in our patient mediated by baclofen and propofol. Our patient probably had a smaller CSF baclofen level that was sufficient to prevent the occurrence of withdrawal syndrome but not to prevent the epileptic discharges mediated by GABAA receptor stimulation by propofol because of desensitization of the GABAB receptor that failed to control the release of GABA.
This case report illustrates that the possibility of SLP with propofol administration should be considered when anesthetizing patients receiving baclofen. Further research could help in the understanding of the interactions of propofol with baclofen in seizure-prone patients.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
L. J. Voss, J. W. Sleigh, J. P. M. Barnard, and H. E. Kirsch The Howling Cortex: Seizures and General Anesthetic Drugs Anesth. Analg., November 1, 2008; 107(5): 1689 - 1703. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|